• Citer

Phase i trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

par Jerusalem, Guy;Fasolo, Angelica;Diéras, Véronique;Cardoso, Fatima ;Bergh, Jonas;Vittori, Luc;Zhang, Yufen;Massacesi, Cristian;Sahmoud, Tarek;Gianni, Luca
Référence Breast cancer research and treatment, 125, 2, page (447-455)
Publication Publié, 2011-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase i trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Auteur:	Jerusalem, Guy; Fasolo, Angelica; Diéras, Véronique; Cardoso, Fatima; Bergh, Jonas; Vittori, Luc; Zhang, Yufen; Massacesi, Cristian; Sahmoud, Tarek; Gianni, Luca
Informations sur la publication:	Breast cancer research and treatment, 125, 2, page (447-455)
Statut de publication:	Publié, 2011-01
Sujet CREF:	Cancérologie
Mots-clés:	Everolimus
	HER2-overexpressing metastatic breast cancer
	mTOR
	Phase I
	Trastuzumab
	Vinorelbine
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6806
	info:doi/10.1007/s10549-010-1260-x
	info:scp/78650967232
	info:pmid/21107682